Chesley Taft & Associates LLC Acquires Shares of 8,725 HealthEquity, Inc. (NASDAQ:HQY)

Chesley Taft & Associates LLC bought a new position in shares of HealthEquity, Inc. (NASDAQ:HQY) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 8,725 shares of the company’s stock, valued at approximately $837,000.

Several other hedge funds have also made changes to their positions in HQY. Wasatch Advisors LP lifted its position in HealthEquity by 6.6% during the 3rd quarter. Wasatch Advisors LP now owns 7,758,890 shares of the company’s stock worth $635,065,000 after acquiring an additional 483,269 shares during the period. State Street Corp raised its stake in shares of HealthEquity by 0.8% during the third quarter. State Street Corp now owns 3,131,900 shares of the company’s stock worth $256,346,000 after purchasing an additional 23,613 shares during the last quarter. Clearbridge Investments LLC lifted its holdings in shares of HealthEquity by 1.9% during the second quarter. Clearbridge Investments LLC now owns 2,377,204 shares of the company’s stock worth $204,915,000 after purchasing an additional 43,491 shares during the period. Mackenzie Financial Corp grew its position in HealthEquity by 16.0% in the 2nd quarter. Mackenzie Financial Corp now owns 2,364,521 shares of the company’s stock valued at $203,822,000 after buying an additional 325,906 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in HealthEquity by 0.7% in the 3rd quarter. Geode Capital Management LLC now owns 2,078,977 shares of the company’s stock valued at $170,197,000 after buying an additional 15,145 shares during the period. Institutional investors and hedge funds own 99.55% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently commented on the stock. BTIG Research raised their target price on shares of HealthEquity from $110.00 to $130.00 and gave the stock a “buy” rating in a research note on Thursday, November 14th. Royal Bank of Canada lifted their price objective on HealthEquity from $100.00 to $105.00 and gave the company an “outperform” rating in a report on Tuesday, December 10th. The Goldman Sachs Group started coverage on HealthEquity in a research report on Friday, November 15th. They set a “neutral” rating and a $108.00 target price on the stock. JMP Securities raised their price target on HealthEquity from $105.00 to $107.00 and gave the company a “market outperform” rating in a report on Tuesday, December 10th. Finally, Mizuho began coverage on HealthEquity in a research report on Wednesday, December 4th. They issued an “outperform” rating and a $126.00 price objective for the company. One equities research analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the stock. Based on data from MarketBeat, HealthEquity has an average rating of “Moderate Buy” and a consensus target price of $110.71.

HealthEquity Trading Up 2.3 %

NASDAQ:HQY opened at $104.74 on Wednesday. The company has a market capitalization of $9.08 billion, a PE ratio of 96.09, a price-to-earnings-growth ratio of 1.80 and a beta of 0.54. HealthEquity, Inc. has a 52-week low of $65.01 and a 52-week high of $105.82. The stock has a fifty day simple moving average of $99.04 and a 200-day simple moving average of $86.92. The company has a quick ratio of 3.20, a current ratio of 3.20 and a debt-to-equity ratio of 0.51.

HealthEquity (NASDAQ:HQY) last announced its earnings results on Monday, December 9th. The company reported $0.59 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.71 by ($0.12). HealthEquity had a return on equity of 9.70% and a net margin of 8.41%. During the same quarter last year, the firm posted $0.40 EPS. On average, equities research analysts expect that HealthEquity, Inc. will post 2.32 earnings per share for the current fiscal year.

Insider Activity at HealthEquity

In related news, Director Stuart B. Parker sold 25,000 shares of the business’s stock in a transaction dated Thursday, December 12th. The shares were sold at an average price of $96.72, for a total value of $2,418,000.00. Following the completion of the transaction, the director now owns 19,061 shares of the company’s stock, valued at approximately $1,843,579.92. The trade was a 56.74 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Robert W. Selander sold 8,250 shares of the company’s stock in a transaction dated Monday, December 9th. The shares were sold at an average price of $101.56, for a total transaction of $837,870.00. Following the completion of the transaction, the director now owns 66,469 shares in the company, valued at approximately $6,750,591.64. This trade represents a 11.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 34,289 shares of company stock valued at $3,355,718. 2.20% of the stock is owned by corporate insiders.

HealthEquity Company Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.